Modifying responses of allyl sulfide, indole-3-carbinol and germanium in a rat multi-organ carcinogenesis model.
The modifying potential of allyl sulfide (AS), indole-3-carbinol (I3C) and carboxyethylgermanium sesquioxide (GE) on lesion development was examined in a wide-spectrum initiation model. Groups 1-4 were treated sequentially with diethylnitrosamine (DEN) (100 mg/kg, i.p., single dose), N-methylnitrosourea (MNU) (20 mg/kg, i.p., four doses at days 2, 5, 8 and 11), and N,N-dibutylnitrosamine (DBN) (0.05% in drinking water during weeks 3 and 4). Groups 5-7 received vehicles without carcinogens during the initiation period. Group 8 served as the untreated control. After this initiating procedure, groups 2-7 were administered a diet containing 0.5% AS or I3C and 0.05% GE. All surviving animals were killed 40 weeks after the beginning of the experiment and the target organs were examined. The induction of GST-P+ hepatic foci in rats treated with carcinogens was significantly inhibited by treatment with all three compounds. AS treatment significantly decreased the incidence of hepatic hyperplastic nodules, adenoma of the lung and thyroid, and papillary or nodular hyperplasia of the urinary bladder. Administration of GE also significantly inhibited the development of hepatic nodules and adenoma of the lung and thyroid. However, I3C only inhibited the hyperplastic nodules of the liver. These results demonstrated that this multi-organ initiation model could be useful in confirming organ-specific modification potential and, in addition, the inhibitory effect of AS, I3C and GE on liver, lung, thyroid and urinary bladder carcinogenesis.
Jang
J J
JJ
Department of Anatomical Pathology, Korea Cancer Center Hospital, Seoul.
Cho
K J
KJ
Lee
Y S
YS
Bae
J H
JH
D000498:Allyl Compounds; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004052:Diethylnitrosamine; D004195:Disease Models, Animal; D005857:Germanium / Q000494:pharmacology* / Q000627:therapeutic use; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D007668:Kidney / Q000033:anatomy & histology; D008099:Liver / Q000033:anatomy & histology / Q000187:drug effects; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced; D008168:Lung / Q000033:anatomy & histology; D008297:Male; D008770:Methylnitrosourea; D009374:Neoplasms, Experimental / Q000139:chemically induced* / Q000517:prevention & control; D009602:Nitrosamines; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011916:Rats, Inbred F344; D013440:Sulfides / Q000494:pharmacology* / Q000627:therapeutic use
D000498:Allyl Compounds; D007211:Indoles; D009602:Nitrosamines; D013440:Sulfides; D005857:Germanium; D004052:Diethylnitrosamine; C038491:allyl sulfide; D008770:Methylnitrosourea; C012279:dibutylnitrosamine; C016517:indole-3-carbinol